Fremont, CA (PRWEB) November 15, 2013
Optovue (http://www.optovue.com), a pioneer in spectral-domain optical coherence tomography (SD-OCT), today announced the worldwide launch and availability of Avanti Widefield Enface OCT. Avanti will make its US debut at the annual American Academy of Ophthalmology (AAO) meeting, November 16-19 in New Orleans.
Avanti is a next generation diagnostic device providing an all-in-one solution for posterior and anterior high-speed, high-resolution OCT imaging offering 70,000 A-scans per second, Widefield 3D motion correction and 3 micron digital resolution (sampling). With the next wave of OCT technology innovation in mind, Avanti is designed as a scalable platform to take eye care professionals to the next level in clinical OCT.
“Avanti not only offers the new Widefield 3D Enface OCT scanning to meet today’s clinical needs, this is also a platform for future OCT innovations that will extend the clinical utility of this technology beyond what even the inventors imagined a few short years ago,” stated Jay Wei, Founder and CEO of Optovue.
In addition to its high-speed and high-resolution, Avanti offers a broad range of functionality across multiple clinical applications including:
- 40 ̊ Widefield Enface OCT with SMART™ Motion Correction offering a larger field of view than the standard OCT device
- Simultaneous Multi-Layered Assessment of Peripheral Retina Pathology
- Retina Tracking at 30 frames/second, providing detail and clarity to assess the retina, as well as the ability to monitor patients and track disease progression
- Fovea Location Recognition
- Deep Choroidal Imaging
- Optic Disc, RNFL & Ganglion Cell Complex Assessment
- TCP®: Total Cornea Power
- Pachymetry Mapping
- Epithelial Thickness Mapping (available for international sale only)
Avanti is currently available for worldwide sale and will be displayed and demonstrated at the Optovue booth #3221 at the AAO meeting November 16-19, 2013.
About Avanti™, RTVue®, iVue®, iStand™, iCam™
Avanti is an advanced OCT platform with 70kHz, widfield 3D, motion correction imaging. RTVue was the first FDA-cleared Spectral-Domain OCT launched in the United States, and also the first OCT cleared by the U.S. Food and Drug Administration for both corneal and retinal imaging. The iVue is the compact version of the RTVue offering the same scanning speed and resolution as the larger system and includes scanning and reports for retina, retina nerve fiber and cornea assessment by the clinician. iStand is a rolling floor stand option for iVue. When mounted to iStand, patients are able to be scanned in various positions including the supine position. The iCam is a color, non-mydriatic fundus camera offering high quality color images in a simple, compact and affordable device
Optovue Inc. is a privately-held ophthalmic device company dedicated to working with eye care professionals and clinical researchers to lead the commercialization of new imaging modalities that aid in the diagnosis and monitoring of ocular disease. Optovue has achieved widespread market success through a combination of unique data analysis design, a reputation for excellent customer service, and rapid innovation of its technology in response to physician feedback. The company is headquartered in Fremont, CA, with operations in Encinitas, CA and European operations in Dossenheim, Germany.
For more information, visit http://www.optovue.com.
Sr. Vice President Marketing
Vice President Regulatory Affairs